Several agents targeting VEGFRs, PDGFRs and c-Kit activity are now being introduced for the treatment of sarcomas with promising results like imatinib, sorafenib, sunitinib, anlotinib and pazopanib (16). This evidence concerns the gene KIT and sarcoma.